Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,982
archived clinical trials in
Endocrine

A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors
A Phase 2a, Prospective, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Safety and Efficacy of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Subjects Who Are Currently Being Treated With an Renin-Angiotensin System Inhibitor
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Bethlehem, PA
A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors
A Phase 2a, Prospective, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Safety and Efficacy of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Subjects Who Are Currently Being Treated With an Renin-Angiotensin System Inhibitor
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Bethlehem, PA
Click here to add this to my saved trials
A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors
A Phase 2a, Prospective, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Safety and Efficacy of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Subjects Who Are Currently Being Treated With an Renin-Angiotensin System Inhibitor
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Orangeburg, SC
A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors
A Phase 2a, Prospective, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Safety and Efficacy of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Subjects Who Are Currently Being Treated With an Renin-Angiotensin System Inhibitor
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Orangeburg, SC
Click here to add this to my saved trials
A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors
A Phase 2a, Prospective, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Safety and Efficacy of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Subjects Who Are Currently Being Treated With an Renin-Angiotensin System Inhibitor
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors
A Phase 2a, Prospective, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Safety and Efficacy of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Subjects Who Are Currently Being Treated With an Renin-Angiotensin System Inhibitor
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors
A Phase 2a, Prospective, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Safety and Efficacy of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Subjects Who Are Currently Being Treated With an Renin-Angiotensin System Inhibitor
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Fairfax, VA
A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors
A Phase 2a, Prospective, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Safety and Efficacy of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Subjects Who Are Currently Being Treated With an Renin-Angiotensin System Inhibitor
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Fairfax, VA
Click here to add this to my saved trials
A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors
A Phase 2a, Prospective, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Safety and Efficacy of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Subjects Who Are Currently Being Treated With an Renin-Angiotensin System Inhibitor
Status: Enrolling
Updated:  12/31/1969
Site Reference ID/Investigator# 16564
mi
from
Las Piedras,
A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors
A Phase 2a, Prospective, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Safety and Efficacy of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Subjects Who Are Currently Being Treated With an Renin-Angiotensin System Inhibitor
Status: Enrolling
Updated: 12/31/1969
Site Reference ID/Investigator# 16564
mi
from
Las Piedras,
Click here to add this to my saved trials
Microbiome Insulin Sensitivity Study
Sex Differences in Youth-Onset Type 2 Diabetes: Exploring Mechanisms
Status: Enrolling
Updated:  12/31/1969
Children's Hospital Colorado
mi
from
Aurora, CO
Microbiome Insulin Sensitivity Study
Sex Differences in Youth-Onset Type 2 Diabetes: Exploring Mechanisms
Status: Enrolling
Updated: 12/31/1969
Children's Hospital Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated:  12/31/1969
Alabama Clinical Therapeutics, Llc
mi
from
Birmingham, AL
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated: 12/31/1969
Alabama Clinical Therapeutics, Llc
mi
from
Birmingham, AL
Click here to add this to my saved trials
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated:  12/31/1969
Medical Affiliated Research Center, Inc.
mi
from
Huntsville, AL
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated: 12/31/1969
Medical Affiliated Research Center, Inc.
mi
from
Huntsville, AL
Click here to add this to my saved trials
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated:  12/31/1969
Coastal Clinical Research Inc
mi
from
Mobile, AL
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated: 12/31/1969
Coastal Clinical Research Inc
mi
from
Mobile, AL
Click here to add this to my saved trials
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated:  12/31/1969
Quality of Life Medical and Research Center
mi
from
Tucson, AZ
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated: 12/31/1969
Quality of Life Medical and Research Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated:  12/31/1969
Sc Clinical Research, Inc.
mi
from
Garden Grove, CA
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated: 12/31/1969
Sc Clinical Research, Inc.
mi
from
Garden Grove, CA
Click here to add this to my saved trials
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated:  12/31/1969
Diablo Clinical Reseach Inc.
mi
from
Walnut Creek, CA
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated: 12/31/1969
Diablo Clinical Reseach Inc.
mi
from
Walnut Creek, CA
Click here to add this to my saved trials
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated:  12/31/1969
Innovative Research of West Florida, Inc.
mi
from
Clearwater, FL
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated: 12/31/1969
Innovative Research of West Florida, Inc.
mi
from
Clearwater, FL
Click here to add this to my saved trials
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated:  12/31/1969
Clinical Research of South Florida
mi
from
Coral Gables, FL
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated: 12/31/1969
Clinical Research of South Florida
mi
from
Coral Gables, FL
Click here to add this to my saved trials
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated:  12/31/1969
Pharmax Research Clinic
mi
from
Miami, FL
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated: 12/31/1969
Pharmax Research Clinic
mi
from
Miami, FL
Click here to add this to my saved trials
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated:  12/31/1969
Compass Research East, LLC
mi
from
Oviedo, FL
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated: 12/31/1969
Compass Research East, LLC
mi
from
Oviedo, FL
Click here to add this to my saved trials
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated:  12/31/1969
Central Kentucky Research Associates, Inc.
mi
from
Lexington, KY
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated: 12/31/1969
Central Kentucky Research Associates, Inc.
mi
from
Lexington, KY
Click here to add this to my saved trials
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated:  12/31/1969
Commonwealth Biomedical Research, LLC
mi
from
Madisonville, KY
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated: 12/31/1969
Commonwealth Biomedical Research, LLC
mi
from
Madisonville, KY
Click here to add this to my saved trials
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated:  12/31/1969
Regional Urology
mi
from
Shreveport, LA
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated: 12/31/1969
Regional Urology
mi
from
Shreveport, LA
Click here to add this to my saved trials
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated:  12/31/1969
The Center for Pharmaceutical Research, P.C.
mi
from
Kansas City, MO
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated: 12/31/1969
The Center for Pharmaceutical Research, P.C.
mi
from
Kansas City, MO
Click here to add this to my saved trials
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated:  12/31/1969
Clinical Research Center of Nevada, LLC
mi
from
Las Vegas, NV
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated: 12/31/1969
Clinical Research Center of Nevada, LLC
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated:  12/31/1969
Rochester Clinical Research Inc.
mi
from
Rochester, NY
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated: 12/31/1969
Rochester Clinical Research Inc.
mi
from
Rochester, NY
Click here to add this to my saved trials
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated:  12/31/1969
Lynn Health Science Institute
mi
from
Oklahoma City, OK
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated: 12/31/1969
Lynn Health Science Institute
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated:  12/31/1969
The Clinical Trial Center, LLC
mi
from
Jenkintown, PA
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated: 12/31/1969
The Clinical Trial Center, LLC
mi
from
Jenkintown, PA
Click here to add this to my saved trials
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated:  12/31/1969
Omega Medical Research
mi
from
Warwick, RI
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated: 12/31/1969
Omega Medical Research
mi
from
Warwick, RI
Click here to add this to my saved trials
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated:  12/31/1969
Coastal Carolina Research Center
mi
from
Mount Pleasant, SC
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated: 12/31/1969
Coastal Carolina Research Center
mi
from
Mount Pleasant, SC
Click here to add this to my saved trials
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated:  12/31/1969
Austin Center for Clinical Research
mi
from
Austin, TX
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated: 12/31/1969
Austin Center for Clinical Research
mi
from
Austin, TX
Click here to add this to my saved trials
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated:  12/31/1969
Reseach Across America
mi
from
Dallas, TX
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated: 12/31/1969
Reseach Across America
mi
from
Dallas, TX
Click here to add this to my saved trials
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated:  12/31/1969
Centex Research
mi
from
Houston, TX
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated: 12/31/1969
Centex Research
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated:  12/31/1969
Clinical Trial Network
mi
from
Houston, TX
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated: 12/31/1969
Clinical Trial Network
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated:  12/31/1969
Cetero Research
mi
from
San Antonio, TX
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated: 12/31/1969
Cetero Research
mi
from
San Antonio, TX
Click here to add this to my saved trials
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated:  12/31/1969
Granger Medical Clinic
mi
from
West Valley City, UT
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated: 12/31/1969
Granger Medical Clinic
mi
from
West Valley City, UT
Click here to add this to my saved trials
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated:  12/31/1969
National Clinical Research - Norfolk, Inc.
mi
from
Norfolk, VA
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated: 12/31/1969
National Clinical Research - Norfolk, Inc.
mi
from
Norfolk, VA
Click here to add this to my saved trials
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated:  12/31/1969
National Clinical Research, Inc.
mi
from
Richmond, VA
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated: 12/31/1969
National Clinical Research, Inc.
mi
from
Richmond, VA
Click here to add this to my saved trials
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated:  12/31/1969
Capital Clinical Reseach Center
mi
from
Olympia, WA
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated: 12/31/1969
Capital Clinical Reseach Center
mi
from
Olympia, WA
Click here to add this to my saved trials
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated:  12/31/1969
Rainier Clinical Research Center Inc.
mi
from
Renton, WA
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days
Status: Enrolling
Updated: 12/31/1969
Rainier Clinical Research Center Inc.
mi
from
Renton, WA
Click here to add this to my saved trials
Sapropterin in Individuals With Phenylketonuria
Effects of Sapropterin on Brain and Cognition in Individuals With Phenylketonuria
Status: Enrolling
Updated:  12/31/1969
Washington University
mi
from
Saint Louis, MO
Sapropterin in Individuals With Phenylketonuria
Effects of Sapropterin on Brain and Cognition in Individuals With Phenylketonuria
Status: Enrolling
Updated: 12/31/1969
Washington University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Effects of Atypical Antipsychotic and Valproate Combination Therapy on Glucose and Lipid Metabolism in Schizophrenia
Effects of Atypical Antipsychotic and Valproate Combination Therapy on Glucose and Lipid Metabolism in Schizophrenia
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Effects of Atypical Antipsychotic and Valproate Combination Therapy on Glucose and Lipid Metabolism in Schizophrenia
Effects of Atypical Antipsychotic and Valproate Combination Therapy on Glucose and Lipid Metabolism in Schizophrenia
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Vedolizumab Induction May Prevent Celiac Enteritis
Vedolizumab Induction May Prevent Celiac Enteritis After Gluten Challenge in Established Celiac Patients in Histological Remission
Status: Enrolling
Updated:  12/31/1969
AGA Clinical Research Associates, LLC
mi
from
Egg Harbor Township, NJ
Vedolizumab Induction May Prevent Celiac Enteritis
Vedolizumab Induction May Prevent Celiac Enteritis After Gluten Challenge in Established Celiac Patients in Histological Remission
Status: Enrolling
Updated: 12/31/1969
AGA Clinical Research Associates, LLC
mi
from
Egg Harbor Township, NJ
Click here to add this to my saved trials
Vedolizumab Induction May Prevent Celiac Enteritis
Vedolizumab Induction May Prevent Celiac Enteritis After Gluten Challenge in Established Celiac Patients in Histological Remission
Status: Enrolling
Updated:  12/31/1969
Theresa Stevens
mi
from
Egg Harbor Township, NJ
Vedolizumab Induction May Prevent Celiac Enteritis
Vedolizumab Induction May Prevent Celiac Enteritis After Gluten Challenge in Established Celiac Patients in Histological Remission
Status: Enrolling
Updated: 12/31/1969
Theresa Stevens
mi
from
Egg Harbor Township, NJ
Click here to add this to my saved trials
Pediatric Metabolic Syndrome Study
Pediatric Metabolic Syndrome Study
Status: Enrolling
Updated:  12/31/1969
MUSC
mi
from
Charleston, SC
Pediatric Metabolic Syndrome Study
Pediatric Metabolic Syndrome Study
Status: Enrolling
Updated: 12/31/1969
MUSC
mi
from
Charleston, SC
Click here to add this to my saved trials
Study of AKCEA-ANGPTL3-LRX (ISIS 703802) in Patients With With Familial Partial Lipodystrophy (FPL)
An Open-label Phase 2 Study of ISIS 703802 (AKCEA-ANGPTL3-LRx) Administered Subcutaneously to Subjects With Familial Partial Lipodystrophy
Status: Enrolling
Updated:  12/31/1969
Clinical Site
mi
from
Ann Arbor, MI
Study of AKCEA-ANGPTL3-LRX (ISIS 703802) in Patients With With Familial Partial Lipodystrophy (FPL)
An Open-label Phase 2 Study of ISIS 703802 (AKCEA-ANGPTL3-LRx) Administered Subcutaneously to Subjects With Familial Partial Lipodystrophy
Status: Enrolling
Updated: 12/31/1969
Clinical Site
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Diet, Exercise, Metabolism, and Obesity in Older Women
Diet, Exercise, Metabolism, and Obesity in Older Women:DEMO
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Diet, Exercise, Metabolism, and Obesity in Older Women
Diet, Exercise, Metabolism, and Obesity in Older Women:DEMO
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients.
A Randomized, Double-blind, Placebo-controlled, Multinational, Multicenter Study With Open-label Treatment Extension to Assess the Effect of MIN-102 (IMP) on the Progression of Adrenomyeloneuropathy in Male Patients With X-linked Adrenoleukodystrophy
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients.
A Randomized, Double-blind, Placebo-controlled, Multinational, Multicenter Study With Open-label Treatment Extension to Assess the Effect of MIN-102 (IMP) on the Progression of Adrenomyeloneuropathy in Male Patients With X-linked Adrenoleukodystrophy
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients.
A Randomized, Double-blind, Placebo-controlled, Multinational, Multicenter Study With Open-label Treatment Extension to Assess the Effect of MIN-102 (IMP) on the Progression of Adrenomyeloneuropathy in Male Patients With X-linked Adrenoleukodystrophy
Status: Enrolling
Updated:  12/31/1969
Hospital de la Pitié-Salpêtrière
mi
from
Paris,
A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients.
A Randomized, Double-blind, Placebo-controlled, Multinational, Multicenter Study With Open-label Treatment Extension to Assess the Effect of MIN-102 (IMP) on the Progression of Adrenomyeloneuropathy in Male Patients With X-linked Adrenoleukodystrophy
Status: Enrolling
Updated: 12/31/1969
Hospital de la Pitié-Salpêtrière
mi
from
Paris,
Click here to add this to my saved trials
A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients.
A Randomized, Double-blind, Placebo-controlled, Multinational, Multicenter Study With Open-label Treatment Extension to Assess the Effect of MIN-102 (IMP) on the Progression of Adrenomyeloneuropathy in Male Patients With X-linked Adrenoleukodystrophy
Status: Enrolling
Updated:  12/31/1969
Stanford Univ Med Ctr
mi
from
Stanford, CA
A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients.
A Randomized, Double-blind, Placebo-controlled, Multinational, Multicenter Study With Open-label Treatment Extension to Assess the Effect of MIN-102 (IMP) on the Progression of Adrenomyeloneuropathy in Male Patients With X-linked Adrenoleukodystrophy
Status: Enrolling
Updated: 12/31/1969
Stanford Univ Med Ctr
mi
from
Stanford, CA
Click here to add this to my saved trials
A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients.
A Randomized, Double-blind, Placebo-controlled, Multinational, Multicenter Study With Open-label Treatment Extension to Assess the Effect of MIN-102 (IMP) on the Progression of Adrenomyeloneuropathy in Male Patients With X-linked Adrenoleukodystrophy
Status: Enrolling
Updated:  12/31/1969
Kennedy Krieger Institute
mi
from
Baltimore, MD
A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients.
A Randomized, Double-blind, Placebo-controlled, Multinational, Multicenter Study With Open-label Treatment Extension to Assess the Effect of MIN-102 (IMP) on the Progression of Adrenomyeloneuropathy in Male Patients With X-linked Adrenoleukodystrophy
Status: Enrolling
Updated: 12/31/1969
Kennedy Krieger Institute
mi
from
Baltimore, MD
Click here to add this to my saved trials
Prediction Using Connected Technologies for Diabetes
Prediction Using a Randomized Evaluation of Data Collection Integrated Through Connected Technologies for Diabetes Management
Status: Enrolling
Updated:  12/31/1969
Penn Medicine
mi
from
Philadelphia, PA
Prediction Using Connected Technologies for Diabetes
Prediction Using a Randomized Evaluation of Data Collection Integrated Through Connected Technologies for Diabetes Management
Status: Enrolling
Updated: 12/31/1969
Penn Medicine
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Single-arm Evaluation of the Effect of HCV Treatment on Cardiovascular Disease Risk
A Single-arm Evaluation of the Effect of Elbasvir/Grazoprevir on Cardiometabolic Parameters in Patients With Hepatitis C Infection and Underlying Metabolic Disease
Status: Enrolling
Updated:  12/31/1969
UCLA CARE Ctr
mi
from
Los Angeles, CA
A Single-arm Evaluation of the Effect of HCV Treatment on Cardiovascular Disease Risk
A Single-arm Evaluation of the Effect of Elbasvir/Grazoprevir on Cardiometabolic Parameters in Patients With Hepatitis C Infection and Underlying Metabolic Disease
Status: Enrolling
Updated: 12/31/1969
UCLA CARE Ctr
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Improving Albuminuria Screening Compliance Using a Smartphone Urinalysis Kit
Improving Albuminuria Screening Compliance Using a Smartphone Urinalysis Kit in the Hypertensive Non-Diabetic Population
Status: Enrolling
Updated:  12/31/1969
Geisinger Health System
mi
from
Danville, PA
Improving Albuminuria Screening Compliance Using a Smartphone Urinalysis Kit
Improving Albuminuria Screening Compliance Using a Smartphone Urinalysis Kit in the Hypertensive Non-Diabetic Population
Status: Enrolling
Updated: 12/31/1969
Geisinger Health System
mi
from
Danville, PA
Click here to add this to my saved trials